Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1..
Anticancer Res. 29(2), 737-44.
(2009). Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer..
Br J Cancer. 103(7), 1048-56.
(2010). Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)..
Anticancer Res. 29(2), 745-51.
(2009). Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer..
Breast Cancer Res Treat. 128(2), 447-56.
(2011). Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients..
J Chemother. 21(5), 573-83.
(2009). Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)..
Ann Oncol. 22(4), 827-34.
(2011). Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients..
Gynecol Oncol. 115(1), 97-101.
(2009). Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial..
Cancer Chemother Pharmacol. 71(1), 245-55.
(2013). Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study..
Ann Oncol. 23(6), 1422-7.
(2012). Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)..
Ann Oncol. 24(4), 1011-7.
(2013). A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study..
Breast Cancer Res Treat. 115(1), 87-99.
(2009). A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer..
Cancer Chemother Pharmacol. 65(6), 1009-21.
(2010). Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial..
Cancer Chemother Pharmacol. 69(2), 533-46.
(2012). Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab..
Pharmacogenomics J. 12(6), 468-75.
(2012). Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel..
Pharmacogenomics J. 14(3), 248-55.
(2014).